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Abstract
Zyflamend, a select blend of 10 herbal extracts, effectively inhibits tumor growth using preclinical
models of castrate-resistant prostate cancer (CR-PCa), mediated in part by activating AMPK, a
master energy sensor of the cell. Currently, two predominant upstream kinases are known to
phosphorylate/activate AMPK at Thr172: LKB1, a known tumor suppressor, and CaMKK2, a
tumor promotor over-expressed in a number of cancers. Thus, the overall objective was to
interrogate how Zyflamend activates AMPK and determine the roles of LKB1 and CaMKK2 in this
activation, by targeting upstream mediators of both kinases ± Zyflamend using pharmacologic
and molecular techniques in CWR22Rv1 (CR-PCa cell line) and HeLa (LKB1-null cell line) cells.
Zyflamend-mediated activation of AMPK appears to be LKB1 dependent, while coordinately and
negatively regulating CaMKK2 activity. Zyflamend failed to rescue the activation of AMPK in the
presence of chemical and molecular inhibitors of LKB1 (radicicol & siLKB1), an effect not
observed in the presence of inhibitors of CaMKK2 (STO-609, EGTA) in CWR22Rv1 cells. Using
LKB1-null and catalytically dead LKB1-transfected HeLa cells that constitutively express
CaMKK2, ionomycin (activator of CaMKK2) increased phosphorylation of AMPK, but Zyflamend
had no effect. Zyflamend appears to inhibit CaMKK2 by DAPK-mediated phosphorylation at
Ser511, an effect prevented by a DAPK inhibitor. Alternatively, Zyflamend increased pAMPK only
in HeLa cells transfected with wild type LKB1. Zyflamend increased phosphorylation of PKCζ
[Zeta], a known activator of LKB1, and inhibition of PKCζ reduced LKB1 phosphorylation. Using
various constructs of HeLa cells, nuclear and cytosolic localization of LKB1 and PKCζ,
respectively, were reversed following Zyflamend treatment, consistent with phosphorylation of
AMPK by LKB1 in the cytosol. These results suggest that Zyflamend’s activation of AMPK is
mediated by LKB1, possibly via activation of PKCζ, but independent of CaMKK2. Moreover,
Zyflamend inhibits CaMKK2 activity by a mechanism involving DAPK phosphorylation of CaMKK2
at Ser511.
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Introduction
Prostate cancer is the second leading cause of death for men in the United States [1]. While
early stages of the disease are treatable, with 5-year survival rates near 100%, prognosis for
advanced forms are less promising [2]. Initially, prostate cancer cells rely on androgens for
growth, and chemically-mediated deprivation (hormone deprivation therapy) is a common
therapy that results in cancer regression [3]. Relapse in the absence of androgens (castrateresistant prostate cancer) is inevitable for most individuals and is associated with increased
expression and activation of the androgen receptor, a major determinant in survival [4, 5]. Due
to the poor prognosis of castrate-resistant prostate cancer, concomitant use of natural products
to enhance effectiveness is being explored clinically and experimentally [4, 6-10].

Zyflamend (New Chapter, Inc. Brattleboro, VT) is a poly-herbal supplement derived from the
extracts of ten different herbs: rosemary, turmeric, holy basil, ginger, green tea, hu zhang,
barberry, oregano, Chinese goldthread, and baikal skullcap. Most research using Zyflamend
has focused its effects on a variety of cancer models, including oral [11], mammary [12], bone
[13], pancreas [14, 15], skin [11, 16], colorectal [15], with an emphasis on prostate [6-9, 17-21],
and its beneficial effects appear to be related to the synergy of action of its components [22].
The effects of Zyflamend and its mechanisms on prostate cancer has been reviewed elsewhere
and can be summarized in Figure 1 [3]. Zyflamend inhibits signaling pathways of inflammation,
affects cell survival by enhancing apoptotic and tumor suppressor genes, epigenetically
modifies histones, down regulates the androgen receptor and influences the energetics of the
cell. The latter pathways are critically important in cancer as rapidly dividing cells rely on the
increased synthesis of macromolecules (lipids, proteins, nucleotides, etc) (as reviewed in [23]).
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5’-adenosine monophosphate-activated protein kinase (AMPK) is a key regulator of energy in
the cell and responds to deficits in adenosine triphosphate (ATP). The protein contains a
catalytic subunit (α-subunit), and two regulatory subunits, β and γ-subunits. Under conditions of
energy stress the following occurs, (i) increased levels of AMP or ADP bind to the γ-subunit
causing allosteric activation of the protein (ATP is a competitive inhibitor), (ii) increased affinity
for upstream kinases that target phosphorylation at Thr172 of the α-subunit (increasing catalytic
activity >100 fold), and (iii) reduced affinity for phosphatases that are involved in
dephosphorylation at Thr172 [24-26]. When activated, AMPK is instrumental in inhibiting
anabolic pathways that consume ATP, such as lipogenesis and protein synthesis, and
enhances catabolic pathways that generate ATP, such as fatty acid oxidation [23, 27].

Recently, it was determined that tumor suppressor properties of Zyflamend is associated with
the activation of AMPK and its downstream signaling [10]. This involves inhibiting the
mammalian target of rapamycin complex-1 (mTORC1), the expression of fatty acid synthase
and its regulatory transcription factor (SREBP1c), and inhibiting the activity of acetyl CoA
carboxylase (ACC), a key regulator of the lipogenic pathway. What is not known is how
Zyflamend upregulates AMPK. Four kinases have been identified that activate AMPK at Thr172,
liver kinases B1 (LKB1), calcium-calmodulin kinases kinase-2 (CaMKK2), transforming growth
factor-β activated protein kinase-1 (TAK1) and mixed lineage kinase 3 (MLK3) [28-32]. LKB1
and CaMKK2 are important in a number of cancers, including castrate-resistant prostate cancer
(as reviewed in [33]), while the involvement of TAK1 and MLK3 has yet to be determined. LKB1
responds to increases in AMP and ADP, while increases in intracellular calcium is needed for
activation of CaMKK2 without requiring elevation in AMP or ADP.

Interestingly, while both LKB1 and CaMKK2 are involved in activating AMPK, their effects on
cancer appear to be quite different. LKB1 has anticancer properties because its
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mutation/deletion is associated with a variety of cancers [34]. CaMKK2, on the other hand, is
overexpressed in a number of cancers, including castrate-resistant prostate cancer [35-37].
Therefore, the overall objective of this research was to interrogate how Zyflamend activates
AMPK in a model of castrate-resistant prostate cancer and the roles LKB1 and CaMKK2 play in
that activation.

Chapter I of this thesis begins with an overview of PCa, Zyflamend’s role against PCa, AMPK,
and upstream regulators of AMPK (LKB1 and CaMKK2). In addition, Chapter II investigates
Zyflamend’s regulation of AMPK against PCa by determining the roles of LKB1 and CaMKK2.
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Chapter I

Overview
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Abstract
Prostate cancer (PCa) is the third most deadly cancer in men of the United States. Because PCa
growth is androgen dependent, a common choice of treatment is androgen deprivation therapy
(ADT). However, most tumors eventually become castrate-resistant PCa (CRPC), despite
hormone ablation. This aggressive form of PCa can metastasize to other tissues (i.e. bone and
lung), making the disease fatal within months. Therefore, it is critical to investigate effective
treatments and mechanisms that inhibits CRPC growth. Zyflamend, a select blend of 10 herbal
extracts, has been shown to inhibit CRPC in vitro and in vivo at human equivalent doses.
Zyflamend’s tumor suppressive effects are partly due to the phosphorylation and activation of
AMP-kinase (AMPK), a master energy sensor of the cell that restores homeostasis in response
to metabolic stress. AMPK activation by Zyflamend inhibits lipogenesis and enhances
mitochondrial fatty acid oxidation, depriving proliferating tumor cells of necessary fatty acids for
the generation of new membranes. However, the mechanism of action whereby Zyflamend
phosphorylates AMPK (pAMPK) is unknown. Currently, the literature has identified two
predominant upstream kinases that phosphorylate the catalytic subunit of AMPK at Thr 172,
thereby increasing activity: liver kinase B1 (LKB1) and calcium/calmodulin-dependent protein
kinase kinase 2 (CaMKK2). Inactivation of LKB1 is associated with a variety of cancers, including
reduced expression in PCa tissue and LKB1 knockdown promotes its proliferation. In contrast,
CaMKK2 is overexpressed in a variety of cancers and has been identified as a therapeutic target
and novel biomarker of PCa. Therefore, identifying a therapeutic adjuvant that activates the LKB1AMPK pathway, but simultaneously inhibits CaMKK2 activity could have therapeutic benefits.
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1.0

Prostate Cancer

Prostate cancer (PCa) is a chronic disease of men that begins when cells in the prostate grow
uncontrollably [38]. It is the third most common and deadly cancer of men in the United States [1,
38]. In 2017, the American Cancer Society estimates 161,360 new cases and more than 26,000
deaths from PCa [1]. Although the five year survival rate of localized prostate cancer is 100%,
once the tumor metastasizes, it is difficult to treat and 5-year survival rates drops to 28% [38].

Androgens and PCa
Most prostate cancers are hormone-sensitive and depend on androgens (i.e. testosterone and
dihydrotestosterone) for growth [39].

These androgens bind to and activate the androgen

receptor, a transcription factor that regulates genes necessary for cell growth. Because early
development of PCa is dependent upon androgens, this stage is characterized as androgendependent PCa [39].

Because initial PCa growth is androgen dependent, a common treatment is androgen deprivation
therapy (ADT) which includes blocking the production of androgens and by antagonizing
androgen receptor signaling. This results in tumor regression where patients may enter a
stabilization phase and live with the disease for several years. Although more than 95% of patients
respond to ADT, the cancer eventually relapses and progresses from an androgen-dependent to
an androgen-independent state. This advanced form is commonly referred to as castrate-resistant
prostate cancer (CRPC).

Despite a lack of androgens, robust androgen receptor (AR) signaling is a key characteristic of
CRPC, making the disease difficult to treat, and with metastatic PCa invariably fatal within one to
two years[40]. Androgen receptor gene amplification, mutations in the AR that results in
constitutive activity and over expression of AR co-regulatory proteins is commonly observed in
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CRPCs, suggesting this mechanism is involved with developing androgen independence [5]. In
addition, expression of nuclear receptors such as transcriptional intermediary factor 2 (TIF2) and
steroid receptor coactivator (SCR1) were increased in CRPC in comparison with benign prostatic
hyperplasia and androgen-dependent PCa [5].Together, these alterations in AR gene
amplification, mutations and expression of AR co-regulatory proteins could, in part, explain a
constitutively active AR in a hormone refractory environment.

Treatments
Although ADT is a common treatment in PCa, other treatments may include chemotherapy,
radiation, and immunotherapy. However, PCa tumors can metastasize to other tissues, such as
the bone and lung, making the disease difficult to treat [3]. Because of the unpromising prognosis
of CRPC, it is critical to investigate effective and safe treatments that delay or attenuate CRPC
growth. A growing interest is the use of natural products (i.e. food and herbs) that can augment
the effectiveness of standard therapies [41].

1.1

AMPK: Mechanistic Target of Cancer

Multiple pathways are involved in cancer regulation, but special attention has focused on the role
of cellular metabolism on tumorigenesis, as first proposed by Nobel laureate Otto Warburg nearly
100 years ago [42]. Rapidly proliferating tumor cells generally shift from a catabolic to a more
anabolic state, synthesizing macromolecules needed to sustain cell survival. Therefore, it has
become of interest to switch this metabolic state and deprive tumors of the necessary
macromolecules required for proliferation. A proposed mechanism promoting this metabolic
switch is the activation of AMP-activated protein kinase (AMPK), a major energy sensor of the
cell that responds to adenosine triphosphate (ATP) deficiency (as reviewed by Jeon et al. (2016))
[23].
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Upon activation, AMPK inhibits ATP consuming pathways by inhibiting synthesis of major
macromolecules including the synthesis of fatty acids, proteins, cholesterol, and glucose via
gluconeogenesis, thus preventing cells from building essential nutrients for cell growth (Figure 1)
[27]. Concomitantly, AMPK restores cellular energy homeostasis by increasing fatty acid
oxidation, glucose uptake and glycolysis, oxidative metabolism, and autophagy. Although AMPK
acutely increases glycolysis, in the long term it promotes mitochondrial biogenesis and oxidative
metabolism, antagonizing the Warburg effect [27]. In addition, AMPK inhibits signaling of
mammalian target of rapamycin complex 1 (mTORC1), via phosphorylation of TSC2 and/or
phosphorylation of its regulatory subunit, raptor. Down-regulation of mTORC1 prevents synthesis
of proteins needed for rapid cell growth, such as hypoxia-inducible factor-1α (HIF-1α) [27].

Other tumor suppressive functions of AMPK includes regulation of cyclin-dependent kinases
(CDK), important enzymes that control the cell cycle. AMPK increases protein expression of CDK
inhibitors, such as p21 and p27, which arrest the cell cycle and induces apoptosis [27].
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Figure 1. Summary of AMPK pathways. AMPK switches off anabolic pathways (shown in the
top half) and switches on catabolic pathways (shown in the bottom half) [27].
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Metformin, a pharmacological AMPK activator, is the most commonly prescribed anti-diabetic
drug which lowers blood glucose by: (1) decreasing gluconeogenesis in the liver and (2)
increasing translocation of GLUT4 to the plasma membrane to facilitate glucose entry into extra
hepatic tissues [42]. Importantly, metformin lowers blood glucose independent of insulin, a growth
factor that contributes to cancer risk and incidence [27]. These observations led to epidemiological
studies which determined that diabetic patients taking metformin had a reduced incidence of
cancer compared to patients taking other medications [27, 42]. In regards to PCa treatment,
metformin was found to reduce prostate specific antigen (PSA) levels, which is a common
biomarker of PCa progression [9]. A proposed mechanism of action whereby metformin stimulates
AMPK activation is inhibition of the electron transport chain, thereby reducing mitochondrial ATP
synthesis and increasing AMPK activation [42]. Overall, the activation of AMPK as a tumor
suppressor protein, has become an important target in the treatment of cancer.

AMPK’s Role in Prostate Cancer
Rapidly proliferating PCa cells are driven by an increased need for macromolecules mediated by
lipogenesis, cholesterol synthesis, and protein synthesis, [43, 44] all of which are inhibited by
AMPK activation. AMPK activation inhibits PCa proliferation in androgen-dependent and CRPC
models, suggesting a pivotal role in both early and late stages of the disease [45]. In addition,
AMPK activation was linked to decreased AR and PSA expression, and increased p21 levels [45].
Therefore, because AMPK can regulate multiple oncogenic pathways at once, it has become an
attractive target to inhibit PCa growth [43-47].

Other studies suggest that AMPK’s role in inhibiting PCa growth is controversial and that
activation can either promote tumor suppressive or oncogenic activity [33]. New evidence
indicates that different upstream stimuli of AMPK could determine whether activation signals
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oncogenic or tumor-suppressive pathways [33]. Therefore, to inhibit PCa growth via AMPK,
careful attention should be paid to its upstream regulators [33].

AMPK Structure and Activation
AMPK consists of a catalytic α subunit and regulatory β and γ subunits (Figure 2). Under
conditions of cellular stress, such as nutrient deprivation or hypoxia, there is an increase of
intracellular AMP:ATP ratio. With an increase in AMP, it binds to the γ subunit, resulting in a
conformational change that permits phosphorylation and activation at Thr172 on the α subunit by
select upstream kinases (Figure 2).

1.2

Upstream Regulators of AMPK

Currently, the literature has identified two predominant upstream kinases of AMPKα at Thr172:
liver kinase B 1 (LKB1) [28] and calcium calmodulin dependent kinase kinase 2 (CaMKK2) [29].

LKB1’s Role in Cancer
LKB1 is a serine/threonine kinase that is ubiquitously expressed in adult and fetal tissues [48]. It
is considered a tumor suppressor protein because mutation/inactivation of its gene (STK11) is
associated with a variety of cancers [34]. Mutation of LKB1 is the underlying cause of PeutzJeghers syndrome, a disease characterized by benign tumors in the gastrointestinal tract, with an
increased risk of developing cancer, particularly colorectal and pancreatic cancers [49]. In
pancreatic cancer cells, augmentation of LKB1 induced apoptosis modifies cancer cell survival in
vitro [49]. LKB1 is mutated in ~30% of non-small-cell lung cancers (NSCLC),[50] making it the
third most mutated gene in NSCLC,[49] and 20% of cervical carcinomas [42]. In breast
carcinomas, silencing of LKB1 expression was associated with metastasis and shorter survival
times, and in vivo studies showed LKB1 expression suppressed tumor growth and lung
metastasis, suggesting LKB1 influences breast cancer progression [49]. In regards to PCa, LKB1
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Figure 2. Structure and activation of AMPK. AMPK is a heterotrimeric protein consisting of a
catalytic α subunit and regulatory β and γ subunits. Activation of AMPK requires binding of AMP
to the γ subunit followed by phosphorylation at Thr 172.
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expression is reported to be lower as compared to normal tissue [51, 52]. Similar results were
observed in androgen-independent PCa cells (PC3 and DU145 cells) compared to normal
prostate epithelial cells (RWPE-1), and LKB1 knockdown promoted their proliferation [51].
Consistent with these observations, in a clinical trial involving PCa patients, expression levels of
LKB1 (mRNA and protein) were significantly lower in PCa tissue as compared to normal adjacent
tissue and PSA levels, and survival times were inversely associated with LKB1 expression [52].
Overall, the expression and activation of LKB1 is important in multiple cancers.

LKB1 Structure and Activation
Human LKB1 has 433 amino acids and exists as two isoforms: LKB1 long form (LKB1L) and LKB1
short form (LKB1S) [53]. The N-terminus domain (residues 38-43) contains a signal that localizes
LKB1 in the nucleus where it is inactive [49, 53]. LKB1 activation involves (i) phosphorylation and
(ii) co-localization with two other proteins that results in translocation from the nucleus to the
cytosol [54, 55].
Currently, there are six identified phosphorylation sites of LKB1: Thr 336, Thr 402, Ser 325, Thr
363, Ser 428, and Ser 399. Thr 336 and Thr 402 are auto-phosphorylation sites, while Ser 325,
Thr 363, and Ser 428 can be phosphorylated by upstream kinases [56]. Ser 428 is only found in
LKB1L and is reported to be essential for LKB1-mediated activation of AMPK [53]. However, Ser399 may be a phosphorylation site of LKB1S that is analogous to Ser 428 of LKB1L.[53] Although
LKB1S can activate AMPK,[53, 57] it is primarily found in the testes [57]. Therefore, Ser 428
appears as a fundamental phosphorylation site required for LKB1-AMPK activation in PCa.

Following phosphorylation at Ser 428, LKB1 is bound by STRAD (STE20-Related Adaptor) and
MO25 (Mouse protein 25) to form the active LKB1-STRAD-MO25 complex in the nucleus (Figure
3) [54, 55] (others describe this formation can occur in the cytosol) [48]. STRAD involvement
increases LKB1 activity, while MO25 increases stabilization of the active complex (as reviewed in
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Figure 3. LKB1 activation and translocation. LKB1 is mostly found inactive in the nucleus
where it can be phosphorylated by PKC-Ϛ and form an active complex with STRAD and
MO25. The LKB1-STRAD-MO25 complex is then translocated from the nucleus into the
cytosol where it can phosphorylate AMPK.
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reference [58]). The active LKB1-STRAD-MO25 complex is transported into the cytosol via
exportin proteins (i.e. Exportin 1 and Exportin 7) where it can act on members of the AMP kinase
family, regulating metabolism and growth [54].

PKCϚ
PKCϚ, a serine/threonine kinase, is an atypical isoform from the PKC family of kinases that
does not require calcium or diacylglycerol for activation, but is activated following
phosphorylation at Thr410 by phosphoinositol-dependent kinase-1/2 (PDK-1/2), a downstream
target of PI3 kinase [59]. Following phosphorylation, PKCϚ translocates to the nucleus where it
increases the phosphorylation of LKB1 at Ser428, resulting in LKB1’s translocation to the
cytosol [55]. Interestingly, activation of PKCϚ, via LKB1, has also been reported to inhibit AKT
activity via PTEN phosphorylation in a feedback loop that regulates PI3 kinase signaling [55].

CaMKK2
CaMKK2 (also known as CaMKKβ) is a serine/threonine kinase and a Ca2+/CaM-dependent
protein kinase encoded by the CaMKK2 gene. CaMKK2 protein expression is highest in the brain
and stimulates signaling cascades involved in neuronal differentiation, migration, memory, and
synapse formation [60]. It can influence other physiological processes such as inflammation,
glucose homeostasis, and adiposity [61].

CaMKK2 is a 66-68 kDa protein with N- and C-terminal domains, a serine/threonine kinase
domain, and a regulatory domain formed by auto-inhibitory and CaM binding regions [61]. At rest,
the auto-inhibitory region blocks the active site which is exposed following binding by Ca 2+/CaM
[62]. Therefore, increase in intracellular calcium levels is a key activator of CaMKK2, resulting in
a fully active kinase [61]. Once activated, the most well-known substrates of CaMKK2 are CaMKI
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and CaMKIV, but it can also phosphorylate AMPK [61]. Other studies have suggested that
CaMKK2 is an alternative upstream AMPK kinase when cells are LKB1 deficient [29, 61].

CaMKK2’s Role in PCa
CaMKK2 is consistently reported to be overexpressed in PCa, including CRPC [35, 36] and barely
detectable in normal prostate epithelial cells [63, 64]. The AR, which remains a principal regulator
of PCa growth, upregulates CaMKK2, promoting glucose uptake, glycolysis and anabolic
reactions via AMPK [63]. The link between CaMKK2 and the AR appears to be a feedback loop,
whereby CaMKK2 activation maintains AR function, cell growth, and PCa progression (Figure 4)
[35]. In addition, CaMKK2 knockdown results in reduced AR activity and PSA expression [35].
Consistent with these observations, a clinical trial with PCa patients found high CaMKK2
expression (in conjunction with low miR-224, a target of the CaMKK2 gene) that resulted in PCa
progression and shorter survival times [65]. Overall, the relationship between CaMKK2 and the
AR has become an important target for PCa growth and regulation.

CaMKK2 Inhibition
Phosphorylation of CaMKK2 (pCaMKK2) at certain amino acid residues by upstream kinases is
thought to prevent the binding of Ca2+/CaM, thus inhibiting catalytic activity.[61, 66-68] These
phosphorylation sites include: Ser 100, Ser 495, and Ser 511.[61] Protein kinase A (PKA) and
death-associated protein kinase-1 (DAPK1) have been identified as upstream kinases
responsible for phosphorylation at one or more of these sites [61].

DAPK
DAPK is a family of serine/threonine kinases that are dependent upon Ca2+/CaM for activation
[69]. DAPK1 is considered to be a tumor suppressor protein that increases apoptosis and
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Figure 4. Summary of CaMKK2 and androgen receptor feedback signaling in prostate
cancer [35].
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autophagy [70]. The rise of intracellular calcium activates a Ca2+/CaM-dependent phosphatase,
resulting in the dephosphorylation at Ser 308 of the Ca2+/CaM binding domain of DAPK1, allowing
for Ca2+/CaM binding, activating the enzyme [71]. Recently, it was reported that DAPK1 regulates
phosphorylation of CaMKK2 at Ser 511, thereby inhibiting catalytic activity and increasing
neuronal cell death [66]. However, there is no information in the literature about DAPK-CaMKK2
signaling in cancer.

1.3

Zyflamend

Zyflamend is a polyherbal supplement made from the extracts of ten herbs all of which have been
found to have anti-inflammatory and anti-cancer activity. These components include extracts
from: ginger (Zingiber officinale 12.8%), rosemary (Rosmarinus officinalis 19.2%), oregano
(Origanum vulgare 5.1%), green tea (Camellia sinensis 12.8%), turmeric (Curcuma longa 14.1%),
barberry (Berberis vulgaris 5.1%), Chinese goldthread (Coptis chinensis 5.1%), baikal skullcap
(Scutellaria baicalensis 2.5%), Hu Zhang (Polygonum cuspidatum 10.2%), and holy basil
(Ocimum sanctum 12.8%) (Table 1) [3]. It is a commercial product (New Chapter, Brattleboro,
VT) that has not been found to have serious side effects in any preclinical experimental models
or effects that were different from placebo in clinical studies.

Zyflamend’s Role in Cancer
All herbs within Zyflamend contain constituents that exert anti-inflammatory and anti-cancer
activities (i.e. anti-oxidant, anti-angiogenic, anti-proliferative, and apoptotic activities). In human
melanoma cells, Zyflamend arrested the cell cycle, inhibited migration, and down-regulated cell
growth via apoptosis and autophagy [16]. In a rodent model with pancreatic tumors, Zyflamend,
in combination with gemcitabine (a chemotherapeutic drug), significantly reduced tumor volume
in comparison with groups that received either Zyflamend or gemcitabine alone, suggesting
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Table 1. Components of Zyflamend

Botanical

Representative Bioactive
Compounds

Part used

Method of Extraction

Marker/Component Specifications

Rosemary (19.2%)
(Rosmarinus officinalis)

Rosmarinic acid
Ursolic acid
Carnosol

Leaf
Leaf

Supercritical CO2
Water and alcohol

Diterpene phenols (22-24%), Essential oils (3-5%)
Diterpene phenols (24-26%)

Ginger (12.8%)
(Zingiber officinale)

Gingerol
Shogaol
Paradol

Rhizome
Rhizome

Supercritical CO2
Water and alcohol

Pungent compounds (24-35%), Zingiberene (≥8%)
Pungent compounds (≥ 3%)

Turmeric (14.1%)
Curcuma longa)

Curcumoids
Turmerones

Rhizome
Rhizome

Water and alcohol
Supercritical CO2, water

Curcuminoids (≥11%)
Curcumin (≥0.5%), Total essential oil with α- and βturmerone (70-90%)

Holy Basil (12.8%)
(Ocimum sanctum)

Ursolic acid

Leaves

Water and alcohol

Ursolic acid (2-3%)

Green Tea (12.8%)
(Camellia sinensis)

Epigallocatechin
Epigallocatechin gallate
Epicatechin gallate

Leaves

Water

Polyphenols (≥45%)

Hu Zhang (10.2%)
(Polygonum cuspidatum)

Resveratrol

Radix/Rhizome

Water and alcohol

Resveratrol (≥8%)

Chinese Goldthread (5.1%) Berberine
(Coptis chinensis)
Coptisine

Root

Water and alcohol

Berberine (≥6%)

Barberry (5.1%)
(Berberis vulgaris)

Berberine

Root bark

Water and alcohol

Berberine (≥6%)

Oregano (5.1%)
(Origanum vulgare)

Carvacrol
Linalool
Rosmarinic acid
Thymol

Leaf

Supercritical CO2, water

Essential oils (8-12%), Phenolic antioxidants (≥4.5%)

Baikal Skullcap (2.5%)
(Scutellaria baicalensis)

Baicalin
Baicalein
Wogonin

Root

Water and alcohol

Baicalin (≥17%), Baicalein (≥1.5%),
Wogonin (≥0.4%)

As previously reviewed by Whelan et al (2017) [3].
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Zyflamend may sensitize cancer cells to chemotherapeutic drugs [14]. A major target in cancer
treatment is nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ĸB), a transcription
factor that regulates multiple tumorigenic genes (i.e. anti-apoptotic genes, cell cycle genes,
angiogenesis, and inflammatory cytokines) [13]. Zyflamend was found to down-regulate NF-ĸB
and suppressed cell growth in leukemia, lung adenocarcinoma cells, and pancreatic tumors [13,
14]. In addition, Zyflamend protected pancreatic β-cells from immune cell destruction in a rodent
model pre-disposed to Type 1 diabetes by a proposed process that inhibited NF-ĸB activation
[72].

Zyflamend’s Role in PCa
Although Zyflamend exerts anti-cancer activity in multiple cancers, particular interest has
developed in its role against PCa. The first study published with Zyflamend involved a case report
in a 70-year-old African American male with high grade prostatic intraepithelial neoplasia
(HGPIN), a strong precursor of PCa. After 18 months of Zyflamend supplementation, the patient
was PIN free and had decreased levels of cyclooxygenase (COX-2) activity, an important enzyme
shown to be over-expressed in PCa [18]. This led to a phase 1 clinical trial which examined the
safety and tolerability of Zyflamend supplementation for 18 months in men with HGPIN. By the
end of the study, 48% of subjects had a 25-50% reduction in PSA levels, 60% had benign tissue
versus 26.7% with HGPIN, while 13.3% developed PCa. No serious side effects were reported,
suggesting daily Zyflamend supplementation may be a safe treatment for HGPIN [20]. More
recently, a clinical trial of four patients with advanced PCa who no longer responded to standard
treatments (i.e., HDT, chemotherapy, surgery, immunotherapy) were treated orally with metformin
and/or Zyflamend. By the end of the study, all patients taking Zyflamend, metformin, or the
combination had dramatic decreases in circulating PSA levels [9].
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The positive responses of Zyflamend’s role against PCa has led to further in vivo and in vitro
experimentation to determine its mechanisms of actions, particularly in CRPC. Zyflamend inhibits
CRPC growth by regulating critical mediators of inflammation, energetics, cell survival, and other
signaling pathways, as summarized in Figure 5 [3]. Perhaps the most critical mediator of human
PCa is AR activation in both androgen dependent and CRPC tumors. In a model of CRPC, human
equivalent doses of Zyflamend down-regulates the androgen-receptor and its nuclear localization
[6]. In addition, combined treatment of Zyflamend and bicalutimide (an anti-AR drug),
synergistically inhibited PCa cell growth [21].

Other attractive targets in cancer treatment is to arrest the cell cycle by increasing expression of
CDK inhibitors such as p21 and p27. Zyflamend increased p21 and p27 expression, resulting in
reduced cell proliferation [8]. These effects may be due to its ability to inhibit histone deacetylases
(HDAC) [8]. The hyper-acetylation of histones relaxes the chromatin around DNA, making it more
accessible for transcription factors to increase the expression of CDK inhibitors, like p21. These
results are important since HDACs are reported to be expressed higher in CRPC than in
androgen-dependent PCa models [3].

Inflammation has long been associated with many cancers, including PCa [73]. Zyflamend downregulates multiple targets of pro-inflammatory mediators including NF-ĸB, STAT3, and enzyme
activities of cyclooxygenase-1 and 2 (COX-1/2) and lipoxygenases (LOX) such as 5-LOX and 12LOX [17, 19, 20].

These results have been recapitulated in multiple laboratories studying

Zyflamend’s anti-inflammatory role in models other than PCa, such as pancreatic cancer,
diabetes, obesity, and oral cancer [12, 14, 72, 74].

Zyflamend’s multiple anti-cancer mechanisms could be due to the combination of extracts, rather
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Figure 5. Summary of Zyflamend’s mechanisms of actions in prostate cancer [3].
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than isolated bioactives derived from those extracts. Components of Zyflamend exerted
synergistic activity at physiologically nanomolar concentrations in comparison with individual bioactives at equivalent physiological concentrations [22]. For example, turmeric and Chinese
Goldthread (two components of Zyflamend) inhibited CRPC proliferation and NF-ĸB signaling
greater than their major bioactives in isolation (curcumin and berberine, respectively) [22]. These
results suggest that other compounds of turmeric and Chinese Goldthread are responsible for this
increased sensitivity [3, 22]. However, confirming which combinations of extracts in Zyflamend
accounts for most of its biological activity is not feasible. For example, there are 1024 possible
combinations of the 10 extracts in Zyflamend (as summarized in Table 2). Even testing only 2
items would result in 57 possible combinations. Since the research in this thesis took ~2 years
using only two combinations (control and all 10 extracts), it would be impractical to explore
multiple combinations. Important to this research is the fact that the components in Zyflamend act
synergistically, at physiologically relevant concentrations, against multiple cancers, including
CRPC.

Irregular cellular energetics is a hallmark of cancer that promotes rapid tumor cell proliferation.
Zyflamend is an AMPK activator that switches the energetics of cells from an anabolic to a more
catabolic state, thereby inhibiting cell viability in CRPC [10]. AMPK activation by Zyflamend
inhibited critical mediators of lipogenesis including acetyl CoA carboxylase (ACC), sterol
regulatory element binding protein-1c (SREBP-1c), and fatty acid synthase (FAS) (Figure 6) [10].
These results are important since PCa relies on increased fatty acid synthesis and lipogenesis
for building new cell membranes [44, 45]. In addition, AMPK down-regulated mTORC1 signaling,
an important pathway in protein synthesis via phosphorylation of its regulatory subunit, raptor [10].
Overall, Zyflamend-stimulated AMPK, depriving CRPC cells from synthesizing macronutrients
necessary for rapid cell proliferation.
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Table 2. The number of possible combinations using 1-10 extracts in Zyflamend.

Possible Combinations of Herbal Extracts

Calculation

For all possible combinations using all 10 (includes negative (vehicle) and positive (all 10) controls:

210 = 1024

For all possible combinations using any 9 out of 10 plus negative (vehicle) and positive (all 10) controls:

1022+1+1=1024

For all possible combinations using any 8 out of 10 plus negative (vehicle) and positive (all 10) controls:

1012+1+1=1014

For all possible combinations using any 7 out of 10 plus negative (vehicle) and positive (all 10) controls:

967+1+1=969

For all possible combinations using any 6 out of 10 plus negative (vehicle) and positive (all 10) controls:

847+1+1=849

For all possible combinations using any 5 out of 10 plus negative (vehicle) and positive (all 10) controls:

637+1+1=639

For all possible combinations using any 4 out of 10 plus negative (vehicle) and positive (all 10) controls:

385+1+1=389

For all possible combinations using any 3 out of 10 plus negative (vehicle) and positive (all 10) controls:

175+1+1=177

For all possible combinations using any 2 out of 10 plus negative (vehicle) and positive (all 10) controls:

55+1+1=57

For all possible combinations using any 1 out of 10 plus negative (vehicle) and positive (all 10) controls:

10+1+1=12

Note: These calculations are derived from the following basic formula:

(k!)
([k-r]!) (r!)

k = the number of herbal extracts (10)
r = the number of extracts to be used out of the 10
! = factorial of the number (i.e., “3!” is equivalent to 3 x 2 x 1)
For example: to determine the possible combinations of 5 items (n=5 with each combination) of the 10 extracts, the formula would be:
(10!)
([10-5]!) (5!)

or

(10•9•8•7•6•5•4•3•2•1) = 252
(5•4•3•2•1) (5•4•3•2•1)

However, to calculate all possible combinations of 5 or less (since the calculation above is only for n=5), you have to do the same calculation for
n=4, n=3, n=2 and n=1, and add these all up and then include negative (vehicle) and positive (all 10) controls for the final calculation.
When only calculating all possible combinations for all 10 items (including controls), the following formula can be used: 2 10.

25

Figure 6. Zyflamend activates AMPK and downstream signaling events. AMPK activation
by Zyflamend inhibits lipogenesis by phosphorylating ACC and down-regulating SREBP-1c, a
transcription factor needed for the expression of lipogenic enzymes such as fatty acid synthase
(FAS). In addition, AMPK inhibits protein synthesis by down-regulating mTORC1 via
phosphorylation of its regulatory subunit, Raptor. Overall, AMPK activation by Zyflamend
results in a metabolic switch that deprives tumor cells of macromolecules necessary for
proliferation [10].
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1.4

Research Objectives

Specific Aims
Prostate cancer is the third most deadly cancer of men in the United States. Current standard
treatments of men with metastatic, castrate-resistant forms of PCa are unpromising, particularly
following metastasis, with a survival rate of <2 years. Zyflamend, is a poly-herbal compound that
has been shown to be safe and effective in inhibiting CRPC growth in vitro and in preclinical
experimental models. More specifically, Zyflamend’s tumor suppressive effects are, in part, due
to the phosphorylation and activation of AMPK, a tumor suppressor protein that inhibits
lipogenesis and protein synthesis for rapidly dividing and proliferating PCa cells. The primary
objective of this study is to interrogate how Zyflamend regulates AMPK phosphorylation in a
model of CRPC.

Currently, two kinases have been identified as being important in PCa that phosphorylate AMPK
at Thr172 of the catalytic α subunit: CaMKK2 and LKB1. CaMKK2 is involved in tumor promotion
and regulates AMPK phosphorylation by a rise of intracellular calcium levels, while LKB1
regulates AMPK phosphorylation upon energetic stress.

The central hypothesis, based on preliminary data from our laboratory, is that Zyflamend does
not activate AMPK via CaMKK2, but instead increases its activation via LKB1. Thus, the overall
objective was to interrogate how Zyflamend activates AMPK in a model of CRPC and determine
the roles of LKB1 and CaMKK2 in this activation.

Specific Aim 1: To determine if the phosphorylation and activation of AMPK by Zyflamend is
mediated, in part, by CaMKK2 using pharmacologic and/or molecular techniques in the presence
and absence of Zyflamend.
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Specific Aim 2: To determine if the phosphorylation and activation of AMPK by Zyflamend is
mediated, in part, by LKB1 using pharmacologic and/or molecular techniques in the presence and
absence of Zyflamend.

28
References

29
[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer Statistics, 2017, CA: a cancer journal for clinicians,
67 (2017) 7-30.
[2] K.D. Miller, R.L. Siegel, C.C. Lin, A.B. Mariotto, J.L. Kramer, J.H. Rowland, K.D. Stein, R.
Alteri, A. Jemal, Cancer treatment and survivorship statistics, 2016, CA: a cancer journal for
clinicians, 66 (2016) 271-289.
[3] J. Whelan, Zhao, Y., Huang, E.-C., MacDonald, A. and Donohoe, D., Zyflamend and Prostate
Cancer Therapy. In:, CRC Press. , Boca Raton, FL., 2017.
[4] V. Conteduca, D. Wetterskog, M.T.A. Sharabiani, E. Grande, M.P. Fernandez-Perez, A.
Jayaram, S. Salvi, D. Castellano, A. Romanel, C. Lolli, V. Casadio, G. Gurioli, D. Amadori, A.
Font, S. Vazquez-Estevez, A. Gonzalez Del Alba, B. Mellado, O. Fernandez-Calvo, M.J. MendezVidal, M.A. Climent, I. Duran, E. Gallardo, A. Rodriguez, C. Santander, M.I. Saez, J. Puente, D.
Gasi Tandefelt, A. Wingate, D. Dearnaley, F. Demichelis, U. De Giorgi, E. Gonzalez-Billalabeitia,
G. Attard, Androgen receptor gene status in plasma DNA associates with worse outcome on
enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative
biomarker study, Annals of oncology : official journal of the European Society for Medical
Oncology, (2017).
[5] M.E. Taplin, S.P. Balk, Androgen receptor: a key molecule in the progression of prostate
cancer to hormone independence, Journal of cellular biochemistry, 91 (2004) 483-490.
[6] E.C. Huang, G. Chen, S.J. Baek, M.F. McEntee, J.J. Collier, S. Minkin, J. Biggerstaff, J.
Whelan, Zyflamend reduces the expression of androgen receptor in a model of castrate-resistant
prostate cancer, Nutrition and cancer, 63 (2011) 1287-1296.
[7] E.C. Huang, M.F. McEntee, J. Whelan, Zyflamend, a combination of herbal extracts,
attenuates tumor growth in murine xenograft models of prostate cancer, Nutrition and cancer, 64
(2012) 749-760.
[8] E.C. Huang, Y. Zhao, G. Chen, S.J. Baek, M.F. McEntee, S. Minkin, J.P. Biggerstaff, J.
Whelan, Zyflamend, a polyherbal mixture, down regulates class I and class II histone

30
deacetylases and increases p21 levels in castrate-resistant prostate cancer cells, BMC
complementary and alternative medicine, 14 (2014) 68.
[9] M.A. Bilen, S.H. Lin, D.G. Tang, K. Parikh, M.H. Lee, S.C. Yeung, S.M. Tu, Maintenance
Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series,
Case reports in oncological medicine, 2015 (2015) 471861.
[10] Y. Zhao, D. Donohoe, E.C. Huang, J. Whelan, Zyflamend, a polyherbal mixture, inhibits
lipogenesis and mTORC1 signalling via activation of AMPK, Journal of Functional Foods, 18, Part
A (2015) 147-158.
[11] A. Mohebati, J.B. Guttenplan, A. Kochhar, Z.L. Zhao, W. Kosinska, K. Subbaramaiah, A.J.
Dannenberg, Carnosol, a constituent of Zyflamend, inhibits aryl hydrocarbon receptor-mediated
activation of CYP1A1 and CYP1B1 transcription and mutagenesis, Cancer prevention research
(Philadelphia, Pa.), 5 (2012) 593-602.
[12] K. Subbaramaiah, E. Sue, P. Bhardwaj, B. Du, C.A. Hudis, D. Giri, L. Kopelovich, X.K. Zhou,
A.J. Dannenberg, Dietary polyphenols suppress elevated levels of proinflammatory mediators
and aromatase in the mammary gland of obese mice, Cancer prevention research (Philadelphia,
Pa.), 6 (2013) 886-897.
[13] S.K. Sandur, K.S. Ahn, H. Ichikawa, G. Sethi, S. Shishodia, R.A. Newman, B.B. Aggarwal,
Zyflamend, a polyherbal preparation, inhibits invasion, suppresses osteoclastogenesis, and
potentiates apoptosis through down-regulation of NF-kappa B activation and NF-kappa Bregulated gene products, Nutrition and cancer, 57 (2007) 78-87.
[14] A.B. Kunnumakkara, B. Sung, J. Ravindran, P. Diagaradjane, A. Deorukhkar, S. Dey, C.
Koca, Z. Tong, J.G. Gelovani, S. Guha, S. Krishnan, B.B. Aggarwal, Zyflamend suppresses
growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model
through modulation of multiple targets, International journal of cancer. Journal international du
cancer, 131 (2012) E292-303.

31
[15] J.H. Kim, B. Park, S.C. Gupta, R. Kannappan, B. Sung, B.B. Aggarwal, Zyflamend sensitizes
tumor cells to TRAIL-induced apoptosis through up-regulation of death receptors and downregulation of survival proteins: role of ROS-dependent CCAAT/enhancer-binding proteinhomologous protein pathway, Antioxidants & redox signaling, 16 (2012) 413-427.
[16] S. Ekmekcioglu, C. Chattopadhyay, U. Akar, A. Gabisi, Jr., R.A. Newman, E.A. Grimm,
Zyflamend mediates therapeutic induction of autophagy to apoptosis in melanoma cells, Nutrition
and cancer, 63 (2011) 940-949.
[17] D.L. Bemis, J.L. Capodice, A.G. Anastasiadis, A.E. Katz, R. Buttyan, Zyflamend, a unique
herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer
cells that lack COX-2 expression, Nutrition and cancer, 52 (2005) 202-212.
[18] S. Rafailov, S. Cammack, B.A. Stone, A.E. Katz, The role of Zyflamend, an herbal antiinflammatory, as a potential chemopreventive agent against prostate cancer: a case report,
Integrative cancer therapies, 6 (2007) 74-76.
[19] P. Yang, C. Cartwright, D. Chan, M. Vijjeswarapu, J. Ding, R.A. Newman, Zyflamendmediated inhibition of human prostate cancer PC3 cell proliferation: effects on 12-LOX and Rb
protein phosphorylation, Cancer biology & therapy, 6 (2007) 228-236.
[20] J.L. Capodice, P. Gorroochurn, A.S. Cammack, G. Eric, J.M. McKiernan, M.C. Benson, B.A.
Stone, A.E. Katz, Zyflamend in men with high-grade prostatic intraepithelial neoplasia: results of
a phase I clinical trial, Journal of the Society for Integrative Oncology, 7 (2009) 43-51.
[21] J. Yan, B. Xie, J.L. Capodice, A.E. Katz, Zyflamend inhibits the expression and function of
androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth,
The Prostate, 72 (2012) 244-252.
[22] Y. Zhao, Collier, Jason, Huang, E-C, Whelan, Jay, Tumeric and Chinese goldthread
synergistically inhibit prostate cancer cell proliferation and NF-kB signaling. , Functional Foods in
Health and Disease, 4 (2014) 312-339.

32
[23] S.M. Jeon, Regulation and function of AMPK in physiology and diseases, Experimental &
molecular medicine, 48 (2016) e245.
[24] G.J. Gowans, D.G. Hardie, AMPK: a cellular energy sensor primarily regulated by AMP,
Biochemical Society transactions, 42 (2014) 71-75.
[25] J. Cheng, T. Zhang, H. Ji, K. Tao, J. Guo, W. Wei, Functional characterization of AMPactivated protein kinase signaling in tumorigenesis, Biochimica et biophysica acta, 1866 (2016)
232-251.
[26] D.G. Hardie, F.A. Ross, S.A. Hawley, AMPK: a nutrient and energy sensor that maintains
energy homeostasis, Nature reviews. Molecular cell biology, 13 (2012) 251-262.
[27] D.G. Hardie, D.R. Alessi, LKB1 and AMPK and the cancer-metabolism link - ten years after,
BMC biology, 11 (2013) 36.
[28] S.A. Hawley, M. Davison, A. Woods, S.P. Davies, R.K. Beri, D. Carling, D.G. Hardie,
Characterization of the AMP-activated protein kinase kinase from rat liver and identification of
threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase, The
Journal of biological chemistry, 271 (1996) 27879-27887.
[29] S.A. Hawley, D.A. Pan, K.J. Mustard, L. Ross, J. Bain, A.M. Edelman, B.G. Frenguelli, D.G.
Hardie, Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for
AMP-activated protein kinase, Cell metabolism, 2 (2005) 9-19.
[30] G. Herrero-Martin, M. Hoyer-Hansen, C. Garcia-Garcia, C. Fumarola, T. Farkas, A. LopezRivas, M. Jaattela, TAK1 activates AMPK-dependent cytoprotective autophagy in TRAIL-treated
epithelial cells, The EMBO journal, 28 (2009) 677-685.
[31] M. Momcilovic, S.P. Hong, M. Carlson, Mammalian TAK1 activates Snf1 protein kinase in
yeast and phosphorylates AMP-activated protein kinase in vitro, The Journal of biological
chemistry, 281 (2006) 25336-25343.
[32] L. Luo, S. Jiang, D. Huang, N. Lu, Z. Luo, MLK3 phophorylates AMPK independently of LKB1,
PloS one, 10 (2015) e0123927.

33
[33] A.S. Khan, D.E. Frigo, A spatiotemporal hypothesis for the regulation, role, and targeting of
AMPK in prostate cancer, Nature reviews. Urology, 14 (2017) 164-180.
[34] R.Y. Gan, H.B. Li, Recent progress on liver kinase B1 (LKB1): expression, regulation,
downstream signaling and cancer suppressive function, International journal of molecular
sciences, 15 (2014) 16698-16718.
[35] L.G. Karacosta, B.A. Foster, G. Azabdaftari, D.M. Feliciano, A.M. Edelman, A regulatory
feedback loop between Ca2+/calmodulin-dependent protein kinase kinase 2 (CaMKK2) and the
androgen receptor in prostate cancer progression, The Journal of biological chemistry, 287 (2012)
24832-24843.
[36] L.G. Karacosta, L.A. Kuroski, W.A. Hofmann, G. Azabdaftari, M. Mastri, A.M. Gocher, S. Dai,
A.J. Hoste, A.M. Edelman, Nucleoporin 62 and Ca2+/calmodulin dependent kinase kinase 2
regulate androgen receptor activity in castrate resistant prostate cancer cells, The Prostate, 76
(2016) 294-306.
[37] F. Lin, K.L. Marcelo, K. Rajapakshe, C. Coarfa, A. Dean, N. Wilganowski, H. Robinson, E.
Sevick, K.D. Bissig, L.C. Goldie, A.R. Means, B. York, The camKK2/camKIV relay is an essential
regulator of hepatic cancer, Hepatology (Baltimore, Md.), 62 (2015) 505-520.
[38] Key Statistics for Prostate Cancer, in, 2016.
[39] S.M. Lee RJ, Hormone Therapy for Prostate Cancer 5th ed., Wolters Kluwer: Lippincott
Williams & Wilkins, Chabner BA, Longo DL,, 2011.
[40] D.M. Savarese, S. Halabi, V. Hars, W.L. Akerley, M.E. Taplin, P.A. Godley, A. Hussain, E.J.
Small, N.J. Vogelzang, Phase II study of docetaxel, estramustine, and low-dose hydrocortisone
in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and
Leukemia Group B, Journal of clinical oncology : official journal of the American Society of Clinical
Oncology, 19 (2001) 2509-2516.
[41] D.G. Hardie, AMPK: a target for drugs and natural products with effects on both diabetes and
cancer, Diabetes, 62 (2013) 2164-2172.

34
[42] D.B. Shackelford, R.J. Shaw, The LKB1-AMPK pathway: metabolism and growth control in
tumour suppression, Nature reviews. Cancer, 9 (2009) 563-575.
[43] R. Flavin, G. Zadra, M. Loda, Metabolic alterations and targeted therapies in prostate cancer,
The Journal of pathology, 223 (2011) 283-294.
[44] X. Xiang, A.K. Saha, R. Wen, N.B. Ruderman, Z. Luo, AMP-activated protein kinase
activators can inhibit the growth of prostate cancer cells by multiple mechanisms, Biochemical
and biophysical research communications, 321 (2004) 161-167.
[45] G. Zadra, C. Photopoulos, S. Tyekucheva, P. Heidari, Q.P. Weng, G. Fedele, H. Liu, N.
Scaglia, C. Priolo, E. Sicinska, U. Mahmood, S. Signoretti, N. Birnberg, M. Loda, A novel direct
activator of AMPK inhibits prostate cancer growth by blocking lipogenesis, EMBO molecular
medicine, 6 (2014) 519-538.
[46] J.L. Wright, J.L. Stanford, Metformin use and prostate cancer in Caucasian men: results from
a population-based case-control study, Cancer causes & control : CCC, 20 (2009) 1617-1622.
[47] M. Zakikhani, R.J. Dowling, N. Sonenberg, M.N. Pollak, The effects of adiponectin and
metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase,
Cancer prevention research (Philadelphia, Pa.), 1 (2008) 369-375.
[48] Z. Xie, Y. Dong, J. Zhang, R. Scholz, D. Neumann, M.H. Zou, Identification of the serine 307
of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and
endothelial cell angiogenesis, Molecular and cellular biology, 29 (2009) 3582-3596.
[49] S.E. Korsse, M.P. Peppelenbosch, W. van Veelen, Targeting LKB1 signaling in cancer,
Biochimica et biophysica acta, 1835 (2013) 194-210.
[50] D. Han, S.J. Li, Y.T. Zhu, L. Liu, M.X. Li, LKB1/AMPK/mTOR signaling pathway in non-smallcell lung cancer, Asian Pacific journal of cancer prevention : APJCP, 14 (2013) 4033-4039.
[51] P. Xu, F. Cai, X. Liu, L. Guo, LKB1 suppresses proliferation and invasion of prostate cancer
through hedgehog signaling pathway, International journal of clinical and experimental pathology,
7 (2014) 8480-8488.

35
[52] J. Lu, P. Sun, B. Sun, C. Wang, Low LKB1 Expression Results in Unfavorable Prognosis in
Prostate Cancer Patients, Medical science monitor : international medical journal of experimental
and clinical research, 21 (2015) 3722-3727.
[53] H. Zhu, C.M. Moriasi, M. Zhang, Y. Zhao, M.H. Zou, Phosphorylation of serine 399 in LKB1
protein short form by protein kinase Czeta is required for its nucleocytoplasmic transport and
consequent AMP-activated protein kinase (AMPK) activation, The Journal of biological chemistry,
288 (2013) 16495-16505.
[54] W. van Veelen, S.E. Korsse, L. van de Laar, M.P. Peppelenbosch, The long and winding
road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling,
Oncogene, 30 (2011) 2289-2303.
[55] P. Song, Z. Xie, Y. Wu, J. Xu, Y. Dong, M.H. Zou, Protein kinase Czeta-dependent LKB1
serine 428 phosphorylation increases LKB1 nucleus export and apoptosis in endothelial cells,
The Journal of biological chemistry, 283 (2008) 12446-12455.
[56] Z. Xie, Y. Dong, M. Zhang, M.Z. Cui, R.A. Cohen, U. Riek, D. Neumann, U. Schlattner, M.H.
Zou, Activation of protein kinase C zeta by peroxynitrite regulates LKB1-dependent AMPactivated protein kinase in cultured endothelial cells, The Journal of biological chemistry, 281
(2006) 6366-6375.
[57] F.C. Denison, N.J. Hiscock, D. Carling, A. Woods, Characterization of an alternative splice
variant of LKB1, The Journal of biological chemistry, 284 (2009) 67-76.
[58] M. Sebbagh, S. Olschwang, M.J. Santoni, J.P. Borg, The LKB1 complex-AMPK pathway: the
tree that hides the forest, Familial cancer, 10 (2011) 415-424.
[59] Z. Xie, Y. Dong, R. Scholz, D. Neumann, M.H. Zou, Phosphorylation of LKB1 at serine 428
by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated
protein kinase in endothelial cells, Circulation, 117 (2008) 952-962.
[60] CaMKK2 Gene in, Weizmann Institute of Science, 1996-2017.

36
[61] L. Racioppi, A.R. Means, Calcium/calmodulin-dependent protein kinase kinase 2: roles in
signaling and pathophysiology, The Journal of biological chemistry, 287 (2012) 31658-31665.
[62] M.T. O'Brien, J.S. Oakhill, N.X. Ling, C.G. Langendorf, A. Hoque, T.A. Dite, A.R. Means, B.E.
Kemp, J.W. Scott, Impact of Genetic Variation on Human CaMKK2 Regulation by Ca2+Calmodulin and Multisite Phosphorylation, Scientific reports, 7 (2017) 43264.
[63] C.E. Massie, A. Lynch, A. Ramos-Montoya, J. Boren, R. Stark, L. Fazli, A. Warren, H. Scott,
B. Madhu, N. Sharma, H. Bon, V. Zecchini, D.M. Smith, G.M. Denicola, N. Mathews, M. Osborne,
J. Hadfield, S. Macarthur, B. Adryan, S.K. Lyons, K.M. Brindle, J. Griffiths, M.E. Gleave, P.S.
Rennie, D.E. Neal, I.G. Mills, The androgen receptor fuels prostate cancer by regulating central
metabolism and biosynthesis, The EMBO journal, 30 (2011) 2719-2733.
[64] L. Racioppi, CaMKK2: a novel target for shaping the androgen-regulated tumor ecosystem,
Trends in molecular medicine, 19 (2013) 83-88.
[65] H. Fu, H.C. He, Z.D. Han, Y.P. Wan, H.W. Luo, Y.Q. Huang, C. Cai, Y.X. Liang, Q.S. Dai,
F.N. Jiang, W.D. Zhong, MicroRNA-224 and its target CAMKK2 synergistically influence tumor
progression and patient prognosis in prostate cancer, Tumour biology : the journal of the
International Society for Oncodevelopmental Biology and Medicine, 36 (2015) 1983-1991.
[66] A.M. Schumacher, J.P. Schavocky, A.V. Velentza, S. Mirzoeva, D.M. Watterson, A
calmodulin-regulated protein kinase linked to neuron survival is a substrate for the calmodulinregulated death-associated protein kinase, Biochemistry, 43 (2004) 8116-8124.
[67] D. Gozuacik, S. Bialik, T. Raveh, G. Mitou, G. Shohat, H. Sabanay, N. Mizushima, T.
Yoshimori, A. Kimchi, DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase
activation and autophagic cell death, Cell death and differentiation, 15 (2008) 1875-1886.
[68] S. Bialik, A. Kimchi, The death-associated protein kinases: structure, function, and beyond,
Annual review of biochemistry, 75 (2006) 189-210.
[69] K. Temmerman, B. Simon, M. Wilmanns, Structural and functional diversity in the activity and
regulation of DAPK-related protein kinases, The FEBS journal, 280 (2013) 5533-5550.

37
[70] P. Singh, P. Ravanan, P. Talwar, Death Associated Protein Kinase 1 (DAPK1): A Regulator
of Apoptosis and Autophagy, Frontiers in molecular neuroscience, 9 (2016) 46.
[71] S. Wang, X. Shi, H. Li, P. Pang, L. Pei, H. Shen, Y. Lu, DAPK1 Signaling Pathways in Stroke:
from Mechanisms to Therapies, Molecular neurobiology, (2016).
[72] S.J. Burke, M.D. Karlstad, C.P. Conley, D. Reel, J. Whelan, J.J. Collier, Dietary polyherbal
supplementation decreases CD3+ cell infiltration into pancreatic islets and prevents
hyperglycemia in nonobese diabetic mice, Nutrition research (New York, N.Y.), 35 (2015) 328336.
[73] S.I. Grivennikov, F.R. Greten, M. Karin, Immunity, inflammation, and cancer, Cell, 140 (2010)
883-899.
[74] P. Yang, Z. Sun, D. Chan, C.A. Cartwright, M. Vijjeswarapu, J. Ding, X. Chen, R.A. Newman,
Zyflamend

reduces

LTB4

formation

and

prevents

oral

carcinogenesis

in

a

7,12-

dimethylbenz[alpha]anthracene (DMBA)-induced hamster cheek pouch model, Carcinogenesis,
29 (2008) 2182-2189.

38
Chapter II

Concurrent regulation of LKB1 and CaMKK2 in the activation of AMPK by Zyflamend, a
polyherbal mixture with anticancer properties.
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Abstract
Zyflamend, a select blend of 10 herbal extracts, effectively inhibits tumor growth using
preclinical models of castrate-resistant prostate cancer (CR-PCa), mediated in part by activating
AMPK, a master energy sensor of the cell. Currently, two predominant upstream kinases are
known to phosphorylate/activate AMPK at Thr172: LKB1, a known tumor suppressor, and
CaMKK2, a tumor promotor over-expressed in a number of cancers. Thus, the overall objective
was to interrogate how Zyflamend activates AMPK and determine the roles of LKB1 and
CaMKK2 in this activation, by targeting upstream mediators of both kinases ± Zyflamend using
pharmacologic and molecular techniques in CWR22Rv1 (CR-PCa cell line) and HeLa (LKB1null cell line) cells. Zyflamend-mediated activation of AMPK appears to be LKB1 dependent,
while coordinately and negatively regulating CaMKK2 activity. Zyflamend failed to rescue the
activation of AMPK in the presence of chemical and molecular inhibitors of LKB1 (radicicol &
siLKB1), an effect not observed in the presence of inhibitors of CaMKK2 (STO-609, EGTA) in
CWR22Rv1 cells. Using LKB1-null and catalytically dead LKB1-transfected HeLa cells that
constitutively express CaMKK2, ionomycin (activator of CaMKK2) increased phosphorylation of
AMPK, but Zyflamend had no effect. Zyflamend appears to inhibit CaMKK2 by DAPK-mediated
phosphorylation at Ser511, an effect prevented by a DAPK inhibitor. Alternatively, Zyflamend
increased pAMPK only in HeLa cells transfected with wild type LKB1. Zyflamend increased
phosphorylation of PKCζ, a known activator of LKB1, and inhibition of PKCζ reduced LKB1
phosphorylation. Using various constructs of HeLa cells, nuclear and cytosolic localization of
LKB1 and PKCζ, respectively, were reversed following Zyflamend treatment, consistent with
phosphorylation of AMPK by LKB1 in the cytosol. These results suggest that Zyflamend’s
activation of AMPK is mediated by LKB1, possibly via activation of PKCζ, but independent of
CaMKK2. Moreover, Zyflamend inhibits CaMKK2 activity by a mechanism involving DAPK
phosphorylation of CaMKK2 at Ser511.
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2.0 Introduction
Prostate cancer is the third leading cause of death for men in the United States [1]. While early
stages of the disease are treatable, with 5-year survival rates near 100%, prognosis for
advanced forms are less promising [2]. Initially, prostate cancer cells rely on androgens for
growth, and chemically-mediated deprivation (hormone deprivation therapy) is a common
therapy that results in cancer regression [3]. Relapse in the absence of androgens (castrateresistant prostate cancer) is inevitable for most individuals and is associated with increased
expression and activation of the androgen receptor, a major determinant in survival [4, 5]. Due
to the poor prognosis of castrate-resistant prostate cancer, concomitant use of natural products
to enhance effectiveness is being explored clinically and experimentally [4, 6-10].

Zyflamend (New Chapter, Inc. Brattleboro, VT) is a poly-herbal supplement derived from the
extracts of ten different herbs: rosemary, turmeric, holy basil, ginger, green tea, hu zhang,
barberry, oregano, Chinese goldthread, and baikal skullcap. Most research using Zyflamend
has focused its effects on a variety of cancer models, including oral [11], mammary [12], bone
[13], pancreas [14, 15], skin [11, 16], colorectal [15], with an emphasis on prostate [6-9, 17-21],
and its beneficial effects appear to be related to the synergy of action of its components [22].
The effects of Zyflamend and its mechanisms on prostate cancer has been reviewed elsewhere
and can be summarized in Figure 1 [3]. Zyflamend inhibits signaling pathways of inflammation,
affects cell survival by enhancing apoptotic and tumor suppressor genes, epigenetically
modifies histones, down regulates the androgen receptor and influences the energetics of the
cell. The latter pathways are critically important in cancer as rapidly dividing cells rely on the
increased synthesis of macromolecules (lipids, proteins, nucleotides, etc) (as reviewed in [23]).
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5’-adenosine monophosphate-activated protein kinase (AMPK) is a key regulator of energy in
the cell and responds to deficits in adenosine triphosphate (ATP). The protein contains a
catalytic subunit (α-subunit), and two regulatory subunits, β and γ-subunits. Under conditions of
energy stress the following occurs, (i) increased levels of AMP or ADP bind to the γ-subunit
causing allosteric activation of the protein (ATP is a competitive inhibitor), (ii) increased affinity
for upstream kinases that target phosphorylation at Thr172 of the α-subunit (increasing catalytic
activity >100 fold), and (iii) reduced affinity for phosphatases that are involved in
dephosphorylation at Thr172 [24-26]. When activated, AMPK is instrumental in inhibiting
anabolic pathways that consume ATP, such as lipogenesis and protein synthesis, and
enhances catabolic pathways that generate ATP, such as fatty acid oxidation [23, 27].

Recently, it was determined that tumor suppressor properties of Zyflamend is associated with
the activation of AMPK and its downstream signaling [10]. This involves inhibiting the
mammalian target of rapamycin complex-1 (mTORC1), the expression of fatty acid synthase
and its regulatory transcription factor (SREBP1c), and inhibiting the activity of acetyl CoA
carboxylase (ACC), a key regulator of the lipogenic pathway. What is not known is how
Zyflamend upregulates AMPK. Four kinases have been identified that activate AMPK at Thr172,
liver kinases B1 (LKB1), calcium-calmodulin kinases kinase-2 (CaMKK2), transforming growth
factor-β activated protein kinase-1 (TAK1) and mixed lineage kinase 3 (MLK3) [28-32]. LKB1
and CaMKK2 are important in a number of cancers, including castrate-resistant prostate cancer
(as reviewed in [33]), while the involvement of TAK1 and MLK3 has yet to be determined. LKB1
responds to increases in AMP and ADP, while increases in intracellular calcium is needed for
activation of CaMKK2 without requiring elevation in AMP or ADP.

42
Interestingly, while both LKB1 and CaMKK2 are involved in activating AMPK, their effects on
cancer appear to be quite different. LKB1 has anticancer properties because its
mutation/deletion is associated with a variety of cancers [34]. CaMKK2, on the other hand, is
overexpressed in a number of cancers, including castrate-resistant prostate cancer [35-37].
Therefore, the overall objective of this paper is to interrogate how Zyflamend activates AMPK in
a model of castrate-resistant prostate cancer and the roles LKB1 and CaMKK2 play in that
activation.

2.1 Materials and Methods
Materials
Zyflamend (New Chapter, Inc. Brattleboro, VT) is composed of the extracts the following herbs
(w/w): rosemary (Rosmarinus officinalis 19.2%), turmeric (Curcuma longa 14.1%), holy basil
(Ocimum sanctum 12.8%), ginger (Zingiber officinale 12.8%), green tea (Camellia sinensis
12.8%), hu zhang (Polygonum cuspidatum 10.2%), barberry (Berberis vulgaris 5.1%), oregano
(Origanum vulgare 5.1%), Chinese goldthread (Coptis chinensis 5.1%), and baikal skullcap
(Scutellaria baicalensis 2.5%). Detailed description and characterization of the preparation of
Zyflamend and quality assurance of the mixture has been described previously in detail [7].
Dulbecco’s Modified Eagle Medium (DMEM), G418, penicillin/streptomycin, puromycin, fetal
bovine serum (FBS) and trypsin were purchased from Invitrogen (Carlsbad, CA). Cloning
vectors were purchased from Addgene (Cambridge, MA) Antibodies for PKC-zeta (PKC-Ϛ),
LKB1, phospho-LKB1, GFP, Histone B, Flag, and Tubulin were from Santa Cruz Biotechnology
(Santa Cruz, CA). AMPK and phospho-AMPK were from Cell Signaling Technology (Beverly,
MA). The following chemical reagents were purchased: 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR) (AdipoGen Life Sciences, San Diego, CA); 1,2-bis(oaminophenoxy)ethane-N,N,N′,N′-tetraacetic acid acetoxymethyl ester (BAPTA-AM) and
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ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA) (Thermo Scientific,
Rockville, IL); STO-609, radicicol, and PKC-Ϛ Pseudo-substrate Inhibitor (Santa Cruz
Biotechnology, Dallas, TX); ionomycin (Sigma-Aldrich, St. Louis, MO); and Death Associated
Protein Kinase Inhibitor (DAPKi) (Merck Millipore, Billerica, MA).

Cell Culture
CWR22Rv1 cells (American Type Culture Collection, Rockville, MD), a human-derived castrateresistant PCa cell line, were cultured in RPMI 1640 media, supplemented with 10% FBS. To
mimic an androgen-depleted state, the cells were incubated overnight with 0.5% FBS. HeLa
cells (ATCC, Rockville, MD), a human-derived cervical cancer cell line that do not express
LKB1, and HCT 116 cells (ATCC, Rockville, MD), a human derived colorectal cancer cell line,
were cultured in DMEM media supplemented with 10% FBS and 25 mM glucose. For
experimental conditions with HeLa cells and HCT 116 cells, All cells were incubated under an
atmosphere of 5% CO2, at 37°C. For activation of AMPK via LKB1-dependent or CaMKK2dependent pathways, cells were treated with AICAR (a cell permeable analog of AMP) (1 mM, 1
hr) or ionomycin (calcium ionophore) (1 µM, 1 hr), respectively. For experiments using inhibitors
of CaMKK2, cells were pre-treated with the selective CaMKK2 inhibitor STO-609 (10 µM, 30
min) or the calcium chelators BAPTA-AM (30 µM, 30 min) or EGTA (2 mM, 30 min). For
inhibition of LKB1 or death-associated protein kinase (DAPK), cells were pre-treated with
radicicol (5 µM, 24 hr) or DAPKi (20 µM, 24 hr), respectively. For inhibition of PKC-ζ, cells were
pre-treated with the selective PKC-ζ pseudo-substrate inhibitor (5 µM, 30 min). For all
experiments involving Zyflamend, cells were treated with Zyflamend at 200 µg/mL for 30 min
unless otherwise indicated.
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Down regulation of LKB1 by small interfering RNA
CWR22Rv1 cells were seeded in RPMI medium containing 10% FBS and incubated overnight
before media was replaced with RNA transfection medium containing 0.5% FBS. Cells were
transfected with 20 nmol of siRNA targeting LKB1 (Thermo Scientific/Dharmacon #L-00503500) and a siRNA non-targeting control (Thermo Scientific/Dharmacon #D-001810-10-05).
Western blot analysis confirmed the efficiency of knockdown to be 76% 48 hr after transfection,
at which time cells were treated with a vehicle or Zyflamend (200 ug/mL) for 30 min.

Overexpression of LKB1 in HeLa cells
When indicated human WT or catalytically dead (KD) mutants of LKB1 were transfected into
HeLa cells using Lipofectamine 3000 (Invitrogen, Carlsbad, CA) following manufacturer’s
guidelines. Cells were cultured for additional 48 hr prior experiments. For total protein lysates,
cells were lysed in radio-immunoprecipitation assay buffer (RIPA: 10 mM Tris-HCl, pH 7.4, 150
mM NaCl, 0.1% sodium dodecyl sulfate [SDS], 1% Triton X-100, 1% sodium deoxycholate, 5
mM EDTA, 1 mM NaF, 1 mM sodium orthovanadate and protease inhibitors). Lysates were
clarified by centrifugation at 13,000 rpm for 10 min, and protein concentrations were determined
using a bicinchoninic acid assay kit (Pierce Chemical). Proteins (10 µg) were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) (8%-12%) [75], transferred to
polyvinylidene difluoride (PVDF) membranes and immunodetected using the indicated
antibodies. Proteins were detected using enhanced chemiluminescence (Amersham
Biosciences). Resulting immunoreactive bands were quantified using FluorChem Q Imaging
software (Alpha Innotech).
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Subcellular fractionation
Following Zyflamend treatment, fractionation was performed in HeLa cells as described
previously with modifications [76, 77]. Briefly, cells were washed with cold buffer A (100 mM
sucrose, 1 mM EGTA, 20 mM MOPS, pH 7.4) and resuspended in lysis buffer B (100 mM
sucrose, 1 mM EGTA, 20 mM MOPS, 0.1 DTT, 5% freshly added percoll, 0.01% digitonin, 1 mM
PMSF and cocktail of protease inhibitors, pH 7,4). Membranes were broken using a dounce
homogenizer (200 strokes/sample). Debris and unbroken cells were removed by centrifugation
(500g for 10 min) and supernatants were then centrifuged (2 500g, 5 min) to separate nuclei
(pellet). Supernatants were centrifuged again (15 000g, 15 min) to separate mitochondria.
Nuclear fraction was resuspended in RIPA buffer containing proteases inhibitors. Cellular
distribution and translocation of the indicated proteins were analyzed by SDS-PAGE and
Western blot as described above. Purity of nuclear and cytoplasmic fractions was verified using
antibodies against histone B and tubulin, respectively.

Western blotting
Cells were lysed in RIPA lysis buffer (Thermo Scientific, Rockford, IL). Protein concentration
was measured using a Bradford protein assay (Thermo Scientific, Rockford, IL). Equal amount
of protein (30 µg) were separated by 8% SDS-PAGE and transferred to a PVDF membrane by
electroblotting. Membranes were blocked by 5% non-fat dry milk (LabScientific, Highlands, NJ)
in 0.1% Tris-buffered saline-Tween-20 (TBST) for 1 hr at room temperature and incubated in
TBST containing primary antibodies overnight at 4°C. Membranes were incubated with antirabbit or anti-mouse secondary antibody conjugated with horseradish peroxidase (HRP) (Cell
Signaling Technology, Danver, MA) for 1 hr at room temperature. Protein expression was
detected with Super Signal West Pico Chemiluminescent Substrate (Thermo Scientific,
Rockford, IL) and membranes were exposed and analyzed via Li-Cor Odyssey FC imaging
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system (Li-Cor, Lincoln, NE). Antibodies against p-AMPKα (Thr172), AMPKα, pACC (Ser79),
ACC, pLKB1 (Ser428), LKB1, pPKCϚ (Thr410), PKCϚ, and pCaMKKβ (Ser511) were used to
detect target protein level at 1:1000. β-Actin or GAPDH (Santa Cruz Biotechnology, Dallas, TX)
was used as the loading control.
ATP Assay
Cellular ATP concentration was determined using a fluorometric ATP assay kit (BioRad,
Milpitas, CA) following the manufacturer’s instructions, and fluorescence was read at 525 nm on
a Glowmax Multi Detection System (Promega Corporation, Madison, WI).

Statistics
For Western blot, protein was analyzed from 3 independent samples and presented as
mean±SEM. For ATP concentration, results are presented as mean±SEM. For multiple
comparisons, data was analyzed using IBM SPSS Statistics 24 and tested by One-Way ANOVA
followed by a Tukey’s post-hoc test. Two-group comparisons were analyzed by two-tailed
Student’s T-test. Results were considered statistically significant at p<0.05.

2.2 Results
Effect of Zyflamend on cell proliferation, ATP levels and AMPK phosphorylation in
CWR22Rv1 cells.
Zyflamend (200 g/mL) inhibited cell proliferation in CWR22Rv1 cells in a concentration and
time dependent manner (data not shown) [8]. Similar results were observed in a variety of
immortalized prostate-derived cells lines [8] and in the HCT116 colorectal cell line (Fig. S.1A).
Because Zyflamend has been shown to change the energetics of CWR22Rv1 cells [3, 10],
levels of ATP were determined. In the presence of Zyflamend, ATP levels were reduced by
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~40% (Fig. 7A) and AMPK phosphorylation (Thr172) increased ~8 fold within 30 min (Fig. 7B
and C), results replicated in HCT116 cells (Fig. S.1B and C).

AMPK activation by CaMKK2 in the presence and absence of Zyflamend in CWR22Rv1
cells.
Zyflamend significantly increased the phosphorylation of AMPK (Thr172) (Fig. 8A and B) and its
downstream target ACC (Ser79) (Fig. 8C and D), results unaffected by pretreatment with the
CaMKK2 inhibitor STO-609 (Fig. 8A-D, lane 4/bar 4). To confirm that the activation of AMPK is
independent of CaMKK2, cells were pre-treated with the calcium chelator BAPTA-AM, as
CaMKK2 activation is dependent upon intracellular calcium. Pretreatment with BAPTA-AM failed
to prevent phosphorylation of AMPK in the presence of Zyflamend (Fig. 8E and F). (Similar
results were obtained using EGTA, another calcium chelator (Fig. S.2). Zyflamend increased the
phosphorylation of CaMKK2 at Ser511 (Fig. 8G), a phosphorylation site that results in its
inhibition and reported to be mediated, in part, by DAPK [66]. Pretreatment with a DAPK
inhibitor attenuated Zyflamend’s ability to increase phosphorylation of CaMKK2 at Ser511 in a
time-dependent manner (Fig. 8H-J).

AMPK activation by LKB1 in the presence and absence of Zyflamend in CWR22Rv1 cells.
Zyflamend significantly increased the phosphorylation of LKB1 (Ser428) (Fig. 9A), AMPK
(Thr172) and ACC (Ser79) (Fig. 9B-F). In the presence of radicicol, a non-specific inhibitor of
LKB1, phosphorylation of AMPK failed to be fully restored following treatment with Zyflamend
(Fig. 9B and C). Likewise, knockdown of LKB1 by siRNA inhibited Zyflamend-mediated
phosphorylation of AMPK and its downstream target ACC (Fig. 9D-F).
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Zyflamend-induced AMPK phosphorylation is LKB1 dependent.
To confirm that Zyflamend-mediated phosphorylation of AMPK is LKB1 dependent and
CaMKK2 independent, we treated LKB1-null HeLa cells, that constitutively express CaMKK2,
with AICAR (an activator of AMPK that is commonly used as a positive control), ionomycin
(activator of CaMKK2) and Zyflamend (Fig. 10). This experiment was repeated in HeLa cells
that were stably transfected with wild-type (WT) LKB1 or a protein that was catalytically dead
(KD) (mutants of the human LKB1), using two different constructs, Flag-tagged or green
fluorescent protein (KD-LKB1 Flag or KD-LKB1 GFP, respectively) (Fig. 10B). In both mutants,
lysine 78 was mutated to isoleucine, abolishing auto-phosphorylation and activation of LKB1
[78, 79]. Ionomycin, but not AICAR or Zyflamend, induced phosphorylation of AMPK in LKB1null HeLa cells (control) (Fig. 10B, columns 1-5). Following transfection with WT-LKB1 (Fig.
10B, columns 6-8), Zyflamend induced phosphorylation of LKB1 and AMPK, an effect more
pronounced with co-treatment of AICAR. However, no phosphorylation of LKB1 and AMPK was
observed in the KD mutants following treatment with Zyflamend and Zyflamend+AICAR (Fig.
10B, columns 9-14).

Zyflamend-mediated LKB1 phosphorylation is linked to PKCzeta.
In an effort to determine how Zyflamend may be mediating the phosphorylation of LKB1, PKCϚ
was investigated as a possible upstream target (Fig. 11). Phosphorylation of PKCϚ and LKB1
increased when CWR22Rv1 cells were treated with Zyflamend (Fig. 11A). However, in the
presence of a highly selective PKCζ pseudo-substrate inhibitor, phosphorylation of LKB1 could
not be restored to control levels following Zyflamend treatment (Fig. 11B and C). Using our
informative HeLa cell constructs, null for LKB1 and cells transfected with WT-LKB1 and KDLKB1, we further investigated the relationship between PKCϚ and LKB1 (Fig. 11D). In HeLa
cells devoid of LKB1 (control cells), PKCϚ is located in the cytosol (Fig. 11D, row 1, column 3),
but appears to translocate to the nucleus upon treatment with Zyflamend (Fig. 11D, row 1,
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column 2). In cells transfected with WT-LKB1, PKCϚ is located in the cytosol (Fig. 11D, row 1,
column 7) and LKB1 is located in the nucleus (Fig. 11D, row 2, column 5). Following Zyflamend
treatment, their locations switch, where PKCϚ translocates to the nucleus (Fig. 11D, row 1,
column 6) and LKB1 is found in the cytosol (Fig. 11D, row 2, column 8). This translocation
following Zyflamend treatment appears to be independent of a catalytically active protein, as the
same results were observed with the KD-LKB1 mutant (Fig. 11D, columns 9-12).

2.3 Discussion
Zyflamend is a unique blend of ten herbal extracts with tumor suppressor properties whose
biochemical and physiological effects have been replicated in different laboratories, at different
times, using different lots, with similar doses/concentrations [6-8, 10, 11, 13-17, 19, 21, 74] .
The quality control of this preparation has been summarized elsewhere [7] and is most likely
responsible for the reproducibility of results. While there is clinical evidence for the beneficial
effects of Zyflamend on prostate cancer [9, 18, 20], it is not possible to tease out the
contributions of each constituent as their effects can be dramatically enhanced when used in
combination [22].

Castrate-resistant prostate cancer is the focus of this research and the research in our
laboratory. To study mechanisms of action, we use human prostate cancer cells derived from
the CWR22 lineage [6-8, 10, 80, 81]. Similar to the progression of human prostate cancer, these
cells are originally androgen dependent and can transform to a castrate-resistant line in vivo
(i.e., CRW22R) following hormone ablation [81-83]. Unlike other prostate cancer cell lines, the
CWR22Rv1 cells express a constitutively active androgen receptor and prostate specific antigen
(PSA), characteristics shared by castrate-resistant prostate cancer in humans.
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The effectiveness of Zyflamend on prostate cancer rests, in part, with its ability to upregulate
AMPK, an effect observed in other cell types [10]. In addition, case studies from M.D. Anderson
Cancer Center report dramatic reductions in PSA levels following Zyflamend and/or metformin
treatment in patients whose prostate cancer no longer responds to standard therapies [9].
Metformin is a known activator of AMPK [41]. However, the mechanism as to how Zyflamend
upregulates AMPK is unknown, although many of its constituents have been shown to
independently activate AMPK by modifying mitochondrial ATP production (as reviewed in [41]).
This is the first paper to delineate the coordination of potential upstream pathways involved in
the activation of AMPK, viz., LKB1 [27] and CaMKK2 [29], especially by natural products.
The role of AMPK in prostate cancer is controversial in the sense that upstream kinases
responsible for its activation appear to have contradictory effects on cancer [33]. CaMKK2 is a
known tumor promotor whose expression is linked to the upregulation of the androgen receptor,
a key step in castrate-resistant prostate cancer [4, 35, 36]. Interestingly, Zyflamend down
regulates the androgen receptor and its nuclear localization [6]. While CaMKK2 has a number of
phosphorylation sites, phosphorylation at Ser511, a sight adjacent to the Ca+2-calmodulin
regulatory domain, prevents autophosphorylation, inhibiting catalytic activity [66]. DAPK is a
kinase in the serine/threonine family of kinases involved in apoptosis and is known to suppress
tumor growth and metastasis [84]. A downstream target of DAPK is CaMKK2 with its
phosphorylation site at Ser511 [66, 68].

In contrast, LKB1 exhibits tumor suppressor properties, where loss of LKB1 is involved in a
variety of cancers [25, 34]. LKB1-mediated activation of AMPK is dependent upon increases in
the AMP(ADP):ATP ratios, an effect observed with Zyflamend. LKB1 contains a nuclear
localization domain and is typically (but not exclusively) found in the nucleus. Following
activation, LKB1 co-localizes with STE20-related adaptor (STRAD) protein and scaffolding
mouse 25 (MO25) protein and translocates to the cytosol where it exerts its kinase activity on a
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number of downstream targets, including AMPK [49, 54]. Nuclear export, in part, appears to
involve phosphorylation at Ser428 by PKCζ [55].

A key finding from this research is that Zyflamend antithetically regulates two parallel pathways
important in the phosphorylation of AMPK that is potentially important in castrate-resistant
prostate cancer. These effects are summarized in Figure 6. Zyflamend-mediated activation of
AMPK appears to be LKB1 dependent, while coordinately and negatively regulating CaMKK2
activity. This was observed using LKB1-null and KD-LKB1 transfected HeLa cells that
constitutively express CaMKK2. The addition of ionomycin (activator of CaMKK2) robustly
increased phosphorylation of AMPK, but Zyflamend (with and without AICAR, an AMP analog)
had no effect. Our results suggest that Zyflamend inhibits CaMKK2 following DAPK-mediated
phosphorylation at Ser511, as this effect is prevented by the presence of a DAPK inhibitor.

On the other hand, Zyflamend robustly increased the phosphorylation of AMPK only in HeLa
cells transfected with WT LKB1. Using the various constructs of the HeLa cells, we confirmed
nuclear localization of LKB1, with translocation to the cytosol following Zyflamend treatment
(Fig. 11). Zyflamend increased phosphorylation of PKCζ, a known activator of LKB1, and
inhibition of PKCζ reduced LKB1 phosphorylation in the presence of Zyflamend.

Importantly, translocation of PKCζ from the cytosol to the nucleus occurred concomitantly.
These results help explain why inhibitors of CaMKK2 (STO-609, EGTA) failed to prevent the
activation of AMPK in the presence of Zyflamend in CWR22Rv1 cells. This was due to the
simultaneous activation of LKB1, and this was confirmed when activation of AMPK (in the
presence of Zyflamend) was not completely rescue following inhibition (radicicol) and
knockdown (siRNA) of LKB1.
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In summary, Zyflamend has been shown to inhibit castrate-resistant prostate cancer, in part,
through the activation of AMPK [10]. In conjunction with reducing ATP levels, this activation is
mediated by the tumor suppressor protein LKB1, via activation of PKCζ. Simultaneously,
Zyflamend inhibits CaMKK2, a tumor promotor that is over-expressed in many cancers,
including castrate-resistant prostate cancer. This inhibition appears to be mediated by DAPK.
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Summary
In summary, PCa is the third leading cause of cancer-related deaths in the United States. The
effectiveness of standard treatments, particularly for metastatic PCa at the castrate-resistant
stage, are unpromising with a survival rate of less than 2 years. However, a growing interest is
the use of natural products that can augment standard therapies of CRPC.

Zyflamend is a natural product composed of ten herbal extracts that may be an effective
adjuvant against PCa, including CRPC. A common target in cancer treatment is activation of
AMPK, a major energy sensor of the cell that inhibits synthesis of macronutrients necessary for
cell growth and survival. Zyflamend inhibits CRPC growth, in part, with its ability to upregulate
AMPK. This study elucidates Zyflamend’s regulation of AMPK activation via two kinases: LKB1
and CaMKK2. LKB1 is a tumor suppressor protein that is reported to be negatively expressed in
multiple cancers, including PCa. Upon energetic stress, AMPK undergoes a conformational
change that increases its affinity for LBK1 binding and subsequent activation. Unlike LKB1,
CaMKK2 is not a tumor suppressor protein, but depends on a rise of intracellular calcium for its
activity and regulation of AMPK. Multiple laboratories have reported CaMKK2 is over-expressed
in CRPC and acts in a feedback loop with the AR, perhaps the most important regulator of PCa
growth. Therefore, inhibiting catalytic activity of CaMKK2 may be a major target to attenuate
CRPC growth.

We find Zyflamend concurrently regulates LKB1 and CaMKK2 in the activation of AMPK.
Zyflamend-mediated AMPK activation appears LKB1 dependent and simultaneously increases
CaMKK2 inhibition, two pathways important in regulating CRPC growth. These results were
observed following chemical inhibition of LKB1, siRNA knockdown, and the use of LKB1-null
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and KD-LKB1 HeLa cells. In addition, WT-LKB1 transfection in HeLa cells resulted in
Zyflamend-stimulated AMPK phosphorylation at its catalytic Thr172 subunit.

On the other side, AMPK activation was not only CaMKK2 independent, but Zyflamend robustly
increased a phosphorylation site (Ser511) identified to inhibit its catalytic activity. These results
are important since CaMKK2 is reportedly linked to the AR in human CRPC. CaMKK2
phosphorylation and inhibition appears mediated by DAPK, a tumor suppressor protein that
regulates apoptosis and autophagy. Overall, to our knowledge, this study is the first to identify a
natural product that concurrently regulates LKB1 and CaMKK2 in AMPK activation. These
findings elucidates Zyflamend’s role as a potential therapeutic adjuvant in the treatment of
prostate cancer.
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Figure 7. Summary of the effects of Zyflamend on prostate cancer (with permission from
reference [3]).
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Figure 8. The effects of Zyflamend on cellular ATP levels and phosphorylation of AMPKα
(at Thr172) in CWR22Rv1 cells. (A) ATP levels of CWR22Rv1 cells treated in the presence or
absence of Zyflamend (200 g/mL, 30 min). (B, C) The effects of Zyflamend (200 g/mL, 30 min
– 3 hr) on phosphorylation of AMPKα in CWR22Rv1 cells. Data is presented as mean±SEM,
n=4. Abbreviations: Con, Control.
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Figure 9. The effects of CaMKK2 inhibition (STO-609) on pAMPKα (at Thr172) and pACC
(at Ser79), phosphorylation of CaMKK2 (at Ser511), and inhibition of DAPK with DAPK
inhibitor ± Zyflamend in CWR22Rv1 cells. (A-D) Western blot of pAMPKα and pACC
following treatment of STO-609 (10 M, 30 min) ± Zyflamend (200 g/mL, 30 min). (E, F)
Western blot of pAMPKα following treatment of BAPTA-AM (30 M, 30 min) ± Zyflamend (200
g/mL, 30 min). (G) Western blot of pCaMKK2 ± Zyflamend (200 g/mL, 30 min – 3hr). (H)
Western blot of pCaMKK2 following treatment of DAPKi (20 M, 1 hr – 24 hr) in the presence of
Zyflamend (200 g/mL, 30 min). (I, J) Western blot and graph comparison of pCaMKK2
following treatment of DAPKi (20 M, 24 hr) ± Zyflamend (200 g/mL, 30 min). Data are
presented as mean±SEM, n=3. Bars with different letters are statistically different at p<0.05.
Abbreviations: BAP, BAPTA-AM; CON, Control; DAPKi, DAPK inhibitor, STO, STO-609; Zyf,
Zyflamend.
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Figure 10. The effects of Zyflamend on phosphorylation of LKB1 (at Ser428) and AMPKα
(at Thr172) following knockdown of LKB1 in CWR22Rv1 cells. (A) Western blot of pLKB1 ±
Zyflamend (200 g/mL, 30 min – 3hr). (B, C) Western blot of pAMPKα following treatment with
radicicol (5 M, 24 hr) ± Zyflamend (200 g/mL, 30 min). (D-F) Western blot of pAMPKα and
pACC (at Ser79) following knockdown of LKB1 ± Zyflamend (200 g/mL, 30 min). Data are
presented as mean±SEM, n=3. Bars with different letters are statistically different at p<0.05.
Abbreviations: CON, Control; Rad, Radicicol; Zyf, Zyflamend.
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Figure 11. Effects of Zyflamend on pAMPK (at Thr172) and pLKB1 (at Ser428) in HeLa
cells null for LKB1, transfected with wild type (WT) LKB1 or with two catalytically dead
(KD) mutants of LKB1. (A) Western blot of pAMPK in HeLa cells ± AICAR, (1 mM, 1 hr),
ionomycin (1 M, 1 hr) or Zyflamend (200 g/mL, 30 min – 3 hr). (B) Western blot of pAMPK in
HeLa cells, WT-LKB1 HeLa cells, and KD-LKB1 HeLa cells ± AICAR (1 mM, 1 hr), ionomycin (1
M, 1 hr), and/or Zyflamend (200 g/mL, 1 hr). Abbreviations: Con, Control; DMSO, dimethyl
sulfoxide; Ion, Ionomycin; Zyf, Zyflamend.
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Figure 12. The effects of Zyflamend on phosphorylation of PKCϚ (at Thr410) and cellular
location of PKCϚ and LKB1 in HeLa cells null for LKB1, transfected with wild type (WT)
LKB1 or with a catalytically dead (KD) mutant of LKB1. (A) Western blot of phosphorylation
of PKCϚ ± Zyflamend (200 g/mL, 30 min – 3 hr). (B,C) Western blot of pLKB1 (at Ser428)
following treatment with Zyflamend, PKCϚ inhibitor (5 M, 30 min) or pretreatment with the
PKCϚ inhibitor plus Zyflamend (200 g/mL, 30 min). (D) Western blot for PKCϚ and LKB1
following subcellular fractionation (cytosol and nucleus) in HeLa cells null for LKB1, transfected
with WT LKB1 or with a KD mutant of LKB1 treated with or without Zyflamend (200 g/mL, 1 hr).
Abbreviations: CON, Control; Pi, PKCϚ inhibitor; Zyf, Zyflamend.
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Figure 13. Summary of the effects of Zyflamend on AMPK regulation by signaling
pathways of LKB1 and CaMKK2. Zyflamend has been shown to inhibit castrate-resistant
prostate cancer, in part, through the activation of AMPK. This activation is mediated by the
increase in AMP:ATP ratio and the activation of the tumor suppressor protein LKB1 following
phosphorylation by PKCζ. Simultaneously, Zyflamend inhibits the tumor promotor CaMKK2 via
phosphorylation at Ser511 by DAPK.
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Figure S.1. The effects of Zyflamend on cell proliferation and phosphorylation of AMPKα
(at Thr172) in HCT 116 cells. (A) MTT assay of HCT 116 cells in the presence or absence of
Zyflamend (50-200 g/mL, 0 hr – 72 hr). (B, C) The effects of Zyflamend (200 g/mL, 3 hr) on
phosphorylation of AMPKα in HCT 116 cells. Data is presented as mean±SEM, n=8 (A) and n=3
(C) and statistically significant at p<0.05. Abbreviations: Con, Control.
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Figure S.2. The effects of CaMKK2 inhibition on pAMPKα ± Zyflamend in CWR22Rv1 cells
following pretreatment with the calcium chelator EGTA. (A, B) Western blot of pAMPKα (at
Thr172) following treatment of EGTA (2 mM, 30 min) ± Zyflamend (200 g/mL, 30 min). Data
are presented as mean±SEM, n=3. Bars with different letters are statistically different at
p<0.05. Abbreviations: CON, Control; EGTA, ethylene glycol-bis (β-aminoethyl ether)-N, N,
N’,N’-tetraacetic acid; Zyf, Zyflamend.
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“But without faith it is impossible to please him; for he that cometh to God must believe
that he is, and that he is a rewarder of them that diligently seek him.”
-

Hebrews 11: 6

“It’s not about how hard you can hit, it’s about how hard you can get hit and keep
moving forward.”
-

Rocky Balboa

“The journey is the reward.”
-

Steve Jobs

